NewsRoom Articles - Page 2 of 41

FridayAug 16, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Oral GLP-1 Alternatives for Diabetes and Obesity Treatment

Lexaria, a global innovator in drug delivery platforms, is exploring its patented DehydraTECH(TM) technology for the oral delivery of glucagon-like peptide-1 (“GLP-1”) drugs. GLP-1 drugs have shown great promise in addressing diabetes and obesity, with nearly all the major brands administered only through injection devices. A previous human study by Lexaria evidenced improved bioavailability when semaglutide was administered orally, as compared to standard Rybelsus®. Lexaria has several additional R&D studies underway, including both animal and human investigations into semaglutide, liraglutide and tirzepatide. Together, those three drugs represent more than 90% of all revenue in the current global GLP1 market. Data…

MondayAug 12, 2024 12:00 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Q3 2024 Financial Results; Offers a Roadmap for its Key GLP-1 Study Program

The company provided updates for its study programs for 2024, with a focus on its glucagon-like peptide-1 (“GLP-1”) agonist research program, targeting a significant step up in addressing worldwide diabetes and obesity, a tremendous market Lexaria has its Human Pilot Study #3 lined up, as well as its chronic dosing human study, both studies will begin dosing later this year Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released its fiscal report for the third quarter of the 2024 financial year (“Q3, 2024”). Of note was growth in cash and marketable securities from $1.5 million during…

ThursdayAug 08, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Alternative Diabetes and Obesity Treatments

Lexaria, a global innovator in drug delivery platforms, is exploring alternatives to traditional diabetes and obesity management through its patented DehydraTECH(TM) technology to potentially enhance oral ingestion vs. injection treatment of GLP-1 drugs The company has made significant strides pairing their bioavailability enhancing DehydraTECH with glucagon-like peptide-1 (“GLP-1”) drugs used for treatment of diabetes and obesity Projections are that by 2030 over 54.9 of Americans could have diabetes, and that by 2045 one in eight adults globally will be living with the condition According to the International Diabetes Federation Diabetes Atlas of 2021, 10.5% of adults aged between 20 and…

WednesdayAug 07, 2024 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”

The report explores the growth, competition, and consumer trends, for lesser known cannabinoids The report highlights a 5.4% revenue increase in the edible market for 2023, with total sales reaching $2.097 billion As consumer preferences shift towards edibles for their therapeutic effects and consistent experiences, the industry product landscape is set to evolve With the increasing acceptance of cannabis use in society, the popularity of edibles—products containing cannabinoids that can be consumed as food or drink—has surged. While many consumers are familiar with edibles containing THC (tetrahydrocannabinol), known for its euphoric effects, or CBD (cannabidiol), recognized for its therapeutic benefits,…

WednesdayJul 31, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Produces Notable Findings in Latest Weight Loss Study

Lexaria, a global innovator in drug delivery platforms, has released interim results from its WEIGHT-A24-1 animal study The study sought to explore the impact of its patented DehydraTECH technology on glucagon-like peptide-1 (“GLP-1”) drugs for the potential treatment of diabetes and weight loss, representing a major global market The first 28 days of dosing yielded positive results that Lexaria’s management described as “noteworthy” It also marked a significant milestone for the company and the first time it has used liraglutide in any of its GLP-1 studies Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery enhancement, just released interim…

WednesdayJul 24, 2024 9:00 am

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration

Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a high unmet medical need Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model Age-related macular degeneration (“AMD”) is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula. This disease significantly impacts the quality of life, making it…

MondayJul 22, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing

Lexaria, a global innovator in drug delivery platforms, recently completed dosing of its human pilot study #2, GLP-1-H24-2 The study is to explore the tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug For Lexaria, the results from this study look to validate earlier studies that have demonstrated improvements in the delivery of semaglutide into the bloodstream Results from the GLP-1-H24-2 study are set to be announced in late August or early September Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the dosing completion of its human pilot study #2, GLP-1-H24-2.…

WednesdayJul 17, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Issuance of Three New Patents, Growing Portfolio to 46 Granted Patents Worldwide

Considered intangible assets, patents offer a significant competitive advantage and value for companies Lexaria Bioscience views its growing patent portfolio as a solid foundation upon which to build future commercial partnerships The company recently announced the receipt of three new patents in the E.U., Canada, and the U.S. The issuance of the latest three patents grows Lexaria’s patent portfolio to 46 granted patents worldwide Lexaria’s multi-patented DehydraTECH(TM) “drug delivery platform technology” offers proven increased bioavailability, enhancing the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of…

TuesdayJul 16, 2024 9:45 am

GEMXX Corp. (GEMZ) Plans to Fully Harness Potential of Two Promising Target Basins in Latin America, Bolstered by Recent Strategic Addition to Primary Investment Target’s Board

GEMXX recently announced the addition of Ali S. Abood to the board of its primary investment target, Latin Energy Partners (“LEP”) The company signed in early June a definitive agreement with LEP to drill four test wells in a highly promising geological formation in Latin America GEMXX and LEP are joining forces to fully harness the potential of two target basins estimated to hold more than 1 billion barrels each of recoverable oil The strategic addition of Mr. Abood to LEP’s board aligns with its commitment to strengthening its investment portfolio and expanding its influence in the global energy sector…

MondayJul 15, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Replicate Results from First GLP-1 Study Following CRO Contract Award for 12-Week Chronic Human Study

Lexaria, a global innovator in drug delivery platforms, recently hired a contract research organization (“CRO”) for its upcoming chronic human study, GLP-1-H24-4 This study will seek to evaluate various glucagon-like peptide-1 (“GLP-1”) formulations, processed with the company’s patented DehydraTECH(TM) technology The study will feature five arms, with each conducted using several investigational sites in Australia Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the hiring of a contract research organization (“CRO”) that will be responsible for overseeing the execution of the company’s upcoming chronic human study, GLP-1-H24-4. This 12-week study will seek to evaluate various…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000